Immunic to Participate in Industry and Investor Conferences in November

Immunic, Inc.(Nasdaq: IMUX),a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following industry and investor conferences in November: — November 3-5:BIO-Europe. Daniel Vitt, Ph.D., Chief Executive Officer of Immunic, Hella Kohlhof, Ph.D., Chief Scientific Officer and Jessica Breu, Vice President […]

CVS HEALTH CORPORATION REPORTS THIRD QUARTER 2025 RESULTS AND UPDATES FULL-YEAR 2025 GUIDANCE

Financial Highlights — Third quarter total revenues increased to a record high $102.9 billion, up 7.8% compared to prior year — Third quarter GAAP diluted loss per share of $3.13, inclusive of a $5.7 billion goodwill impairment charge related to the Health Care Delivery reporting unit — Third quarter Adjusted EPS of $1.60 — Generated

CGI to release fourth quarter and fiscal 2025 results on November 5

Stock Market Symbols GIB.A (TSX) GIB (NYSE) cgi.com/newsroom CGI (TSX: GIB.A) (NYSE: GIB) will release results for its fourth quarter and fiscal year 2025, ended September 30, 2025, on Wednesday, November 5, 2025 before the markets open. Management will host a conference call to discuss results and answer questions at 9:00 a.m. (EDT). Who: François

Alaska and Hawaiian Airlines Reach Major Integration Milestone: a Single Operating Certificate

Alaska Airlines today received a single operating certificate (SOC) from the Federal Aviation Administration to operate alongside Hawaiian Airlines as two separate brands. This significant milestone – a FAA regulatory requirement achieved just over a year after Alaska and Hawaiian combined – marks the successful integration of training, policies, procedures and manuals across both airlines.

Allison Transmission Expands Its Global Network of Authorized Partners to Enhance Support for Cross-Drive Transmissions

Allison Transmission, the world's largest manufacturer of medium- and heavy-duty fully automatic transmissions for commercial and defense vehicles, has significantly expanded its global network of authorized service providers to support its cross-drive transmissions for defense applications. The latest addition to this network is Wojskowe ZakIady Motoryzacyjne (WZM) in Poland, which is now an official channel

PROSPERITY BANCSHARES, INC.® REPORTS THIRD QUARTER 2025 EARNINGS

— Board approved increase in dividend of 3.45% to $0.60 per share for fourth quarter 2025, representing the 22nd consecutive annual increase, with a compound annual growth rate of 10.7% — Net income of $137.6 million and earnings per share (diluted) of $1.45 for third quarter 2025 — Net income of $402.9 million, increased 15.4%,

Verizon Reports 3Q 2025 Earnings Reiterates Full-Year Financial Guidance

(NYSE:VZ),(NASDAQ:VZ), 3Q 2025 Key Results Grew wireless service revenue1 to $21.0 billion Over 18 percent of the company's Consumer postpaid phone customers have a converged offering Raised the dividend for the 19th consecutive year NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) — Verizon Communications Inc. (NYSE, Nasdaq: VZ) today reported third-quarter 2025 results and is

Chart Industries Reports Third Quarter 2025 Financial Results

(NYSE:GTLS),(NASDAQ:BKR),(NYSE:FLS), HOUSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) — Chart Industries, Inc. (NYSE: GTLS) today reported results for the third quarter ended September 30, 2025. On July 28, 2025 Baker Hughes (NASDAQ: BKR) and Chart entered into a definitive agreement for Baker Hughes to acquire all outstanding shares of Chart's common stock for $210 per share

Kyverna Therapeutics Announces Positive Interim Phase 2 Data from KYSA-6 Study of KYV-101 in Generalized Myasthenia Gravis at AANEM 2025

(NASDAQ:KYTX), Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful responses in MG-ADL and QMG — the co-primary endpoints of the Phase 3 trial — with mean reductions of -8.0 pts and -7.7 points at 24

NetraMark Presents AI-Driven Advances in Precision Psychiatry to Enhance Clinical Trial Designs at Joint Autumn Conference

(CNSX:AIAI),(OTC US:AINMF),(Other OTC:AINMF),(Boerse Frankfurt – Freiverkehr:PF0),(CNSX:AIAI.CN), TORONTO, Oct. 29, 2025 (GLOBE NEWSWIRE) — NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, presented two significant applications of its technology at the International

Scroll to Top